| Literature DB >> 36035006 |
Jing Ma1, Jianchen Luo2, Mingqing Xu2.
Abstract
Background: The coronavirus disease of 2019 (COVID-19) has had catastrophic effects worldwide. Mounting efforts for vaccination against COVID-19 have achieved tremendous progress. Online searching is a voluntary behavior of people might reflect the public attention and awareness.. Screening and analyzing the details of vaccine related searches may help the government to grasp the trend of public opinion and provide a reference for vaccination strategies and future efforts to protect public health.Entities:
Keywords: Baidu Index (BDI); Vaccine; coronavirus disease of 2019 (COVID-19); public health
Year: 2022 PMID: 36035006 PMCID: PMC9403913 DOI: 10.21037/atm-22-3064
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839
Figure 1Total relative search volumes curves and vaccination cases. BDI, Baidu Index; COVID-19, coronavirus disease of 2019.
Relevant vaccine policies and events
| Peak | Note | Date | Events |
|---|---|---|---|
| I | a | 2020-01-26 | The Chinese Center for Disease Control and Prevention has begun developing the COVID-19 vaccine |
| b | 2020-02-25 | The world’s first mRNA drug development company has opened the safety clinical trial | |
| c | 2020-03-17 | Recombinant COVI-19 vaccine approved for clinical trials | |
| II | d | 2020-06-04 | China’s NHC Director Ma Xiaowei attended a video conference of the Global Vaccine Summit |
| e | 2020-06-18 | Circular on the issuance of general biosafety requirements for vaccine production workshops | |
| f | 2020-08-11 | Russia has announced the registration of the world’s first COVID-19 vaccine | |
| g | 2020-08-17 | China’s first patent for COVID-19 vaccine was approved | |
| h | 2020-10-16 | Preliminary clinical trial results of a COVID-19 inactivated vaccine in China have been published in the | |
| i | 2020-10-20 | The coronavirus mutation had no substantial impact on vaccine development | |
| 2020-10-20 | COVID-19 vaccine development schedule, priority population, and pricing | ||
| III | j | 2020-12-06 | Five COVID-19 vaccines were tested in phase III clinical trials in China |
| k | 2020-12-19 | Introduction of COVID-19 vaccination in key populations | |
| 2020-12-19 | Vaccination population, location, price, adverse reactions, expiration date, safety of the COVID-19 vaccine | ||
| l | 2020-12-21 | The situation of epidemic prevention and control and vaccination of key groups in winter and spring were introduced | |
| m | 2020-12-31 | China’s first COVID-19 vaccine has been conditionally released and free for all | |
| n | 2021-01-09 | The COVID-19 vaccine is free for all | |
| o | 2021-01-31 | The incidence of severe abnormal reactions reported with COVID-19 vaccines was not higher than with influenza vaccines | |
| IV | p | 2021-02-25 | The State Food and Drug Administration approved the application for registration of recombinant COVID-19 vaccine (adenovirus type 5 vector) of Consino Biosciences with conditions |
| 2021-02-25 | COVID-19 inactivated vaccine (Vero cell) from Sinopharm Wuhan Company was approved by The State Food and Drug Administration with conditions | ||
| q | 2021-03-15 | How long will it take to get other vaccines after the COVID-19 vaccine | |
| r | 2021-03-22 | Mass vaccination of people over the age of 60 will be launched | |
| s | 2021-03-29 | Official technical guidelines for vaccination are issued after 100 million people have been vaccinated | |
| 2021-03-29 | The introduction of COVID-19 vaccination: it should be carried out as soon as possible, promoted step by step, prioritized, and safeguarded | ||
| 2021-03-29 | Technical Guidelines for COVID-19 Vaccination (first edition) | ||
| V | t | 2021-04-29 | Cross-regional vaccination efforts |
| u | 2021-05-14 | Interpretation of the COVID-19 Prevention and Control Plan (Version 8) | |
| v | 2021-05-17 | Deployment of COVID-19 prevention and control and COVID-19 vaccination | |
| w | 2021-05-30 | People’s Daily online released a popular map of COVID-19 vaccination | |
| x | 2021-06-18 | The NHC has deployed COVID-19 prevention and control and COVID-19 vaccination efforts |
The letters a–x are similar in . COVID-19, coronavirus disease of 2019; mRNA, messenger RNA; NHC, National Health Commission.
Figure 2Relative search volumes curves in provinces/cities/region. BDI, Baidu Index; COVID-19, coronavirus disease of 2019.
Results of Pearson correlation
| Projects | COVID-19 vaccine RSV | COVID-19 RSV | Vaccine RSV | |||||
|---|---|---|---|---|---|---|---|---|
| r | P value | r | P value | r | P value | |||
| Vaccinations | 0.382 | <0.001 | 0.081 | 0.422 | 0.256 | 0.010 | ||
| COVID-19 vaccine RSV | – | – | 0.232 | <0.001 | 0.778 | <0.001 | ||
COVID-19, coronavirus disease of 2019; RSV, relative search volume; r, Pearson correlation coefficient.
Results of the mean and max daily RSV among provinces/cities/region
| Provinces/cities/region | Groups | Daily BDI | Peak I | Peak II | Peak III | Peak IV | Peak V | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | Max | Days | Mean | Max | Days | Mean | Max | Days | Mean | Max | Days | Mean | Max | Days | Mean | Max | Days | |||||||
| Beijing | COVID-19 | 965.77 | 3,682 | 548 | 429.12 | 1,277 | 56 | 1,131.49 | 3,682 | 75 | 1,648.35 | 2,615 | 57 | 616.82 | 1,008 | 33 | 822.00 | 1,674 | 51 | |||||
| COVID-19 vaccine | 1,596.73 | 7,912 | 17.23 | 965 | 1,062.80 | 2,615 | 3,509.04 | 7,912 | 2,663.91 | 3,707 | 2,817.78 | 5,134 | ||||||||||||
| Vaccine | 736.01 | 2,063 | 508.45 | 1,763 | 578.09 | 1,897 | 1,195.67 | 2,063 | 998.52 | 1,351 | 906.78 | 1,322 | ||||||||||||
| Guangdong | COVID-19 | 1,444.86 | 6,089 | 604.25 | 1,601 | 1,280.43 | 1,910 | 1,982.54 | 3,423 | 913.91 | 1,315 | 2,500.29 | 6,089 | |||||||||||
| COVID-19 vaccine | 2,628.72 | 31,162 | 23.93 | 1,340 | 1,252.51 | 4,093 | 3,069.33 | 7,668 | 2,910.91 | 8,805 | 11,300.88 | 31,162 | ||||||||||||
| Vaccine | 1,078.28 | 6,375 | 862.70 | 3,076 | 787.64 | 1,805 | 1,204.26 | 2,053 | 982.73 | 2,036 | 2,494.63 | 6,375 | ||||||||||||
| Heilongjiang | COVID-19 | 349.55 | 1,129 | 165.89 | 412 | 293.92 | 553 | 621.88 | 1,129 | 248.73 | 363 | 316.94 | 638 | |||||||||||
| COVID-19 vaccine | 614.30 | 2,847 | 6.95 | 389 | 350.92 | 1,113 | 1,029.56 | 2,654 | 1,044.36 | 2,847 | 1,415.57 | 2,611 | ||||||||||||
| Vaccine | 245.51 | 1,001 | 281.11 | 1,001 | 209.04 | 470 | 268.21 | 412 | 243.88 | 482 | 320.86 | 489 | ||||||||||||
| Shanghai | COVID-19 | 851.77 | 2,744 | 366.30 | 1,208 | 818.89 | 1,729 | 1,322.04 | 2,744 | 524.70 | 767 | 736.41 | 1,416 | |||||||||||
| COVID-19 vaccine | 1,185.51 | 5,052 | 12.59 | 705 | 693.23 | 2,275 | 1,821.00 | 4,932 | 2,140.70 | 4,976 | 2,538.98 | 5,052 | ||||||||||||
| Vaccine | 586.76 | 1,613 | 433.77 | 1,452 | 416.73 | 1,197 | 742.33 | 1,418 | 708.85 | 1,533 | 919.92 | 1,461 | ||||||||||||
| Sichuan | COVID-19 | 716.45 | 3,906 | 381.82 | 1,091 | 640.53 | 1,422 | 1,160.56 | 3,906 | 448.33 | 620 | 704.37 | 1,151 | |||||||||||
| COVID-19 vaccine | 1,089.63 | 7,582 | 16.95 | 949 | 578.68 | 1,783 | 1,604.98 | 7,582 | 1,258.09 | 4,525 | 3,732.90 | 7,524 | ||||||||||||
| Vaccine | 412.52 | 1,505 | 516.70 | 1,505 | 317.53 | 766 | 438.72 | 894 | 340.64 | 712 | 743.45 | 1,228 | ||||||||||||
| Tibet | COVID-19 | 92.08 | 169 | 37.79 | 128 | 96.52 | 152 | 117.51 | 169 | 75.73 | 133 | 100.86 | 146 | |||||||||||
| COVID-19 vaccine | 121.45 | 624 | 1.30 | 73 | 83.31 | 172 | 192.11 | 624 | 143.82 | 330 | 325.41 | 534 | ||||||||||||
| Vaccine | 78.26 | 222 | 55.46 | 146 | 62.67 | 130 | 93.63 | 160 | 82.85 | 143 | 125.10 | 222 | ||||||||||||
| Total | COVID-19 | 8,110.95 | 28,637 | 3,193.04 | 10,003 | 6,841.96 | 17,784 | 15,723.00 | 28,637 | 4,657.55 | 7,149 | 9,574.04 | 17,172 | |||||||||||
| COVID-19 vaccine | 18,856.89 | 148,151 | 153.07 | 8,572 | 6,721.31 | 32,781 | 27,367.26 | 44,689 | 27,960.48 | 77,112 | 74,642.49 | 148,151 | ||||||||||||
| Vaccine | 4,868.81 | 24,439 | 5,223.70 | 24,439 | 3,150.84 | 10,590 | 5,523.18 | 12,681 | 4,617.70 | 9,718 | 11,043.55 | 22,231 | ||||||||||||
RSV, relative search volume; BDI, Baidu Index; COVID-19, coronavirus disease of 2019.
Figure 3Daily average BDI contribution of provinces/cities/region in total. The contribution of daily average BDI of (A) “COVID-19”, (B) “vaccine”, and (C) “COVID-19 vaccine” in different provinces/cities/region. COVID-19, coronavirus disease of 2019; BDI, Baidu Index.